These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15716706

  • 1. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?
    López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, Barba J, Tomás L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuño MA, Díez J.
    J Hypertens; 2005 Mar; 23(3):625-32. PubMed ID: 15716706
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients.
    González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Díez J.
    J Hypertens; 2005 Dec; 23(12):2297-304. PubMed ID: 16269972
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease.
    Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, Martínez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindán JP, Díez J.
    Circulation; 2000 Apr 11; 101(14):1729-35. PubMed ID: 10758057
    [Abstract] [Full Text] [Related]

  • 8. Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?
    Moreno MU, San José G, Pejenaute Á, Landecho MF, Díez J, Beloqui Ó, Fortuño A, Zalba G.
    Hypertension; 2014 Mar 11; 63(3):468-74. PubMed ID: 24324051
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Echocardiographic assessment and N-terminal pro-brain natriuretic peptide in hypertensives with metabolic syndrome.
    Krzesiński P, Uziebło-Życzkowska B, Gielerak G, Stańczyk A, Piotrowicz K, Piechota W, Smurzyński P, Skrobowski A.
    Adv Clin Exp Med; 2017 Mar 11; 26(2):295-301. PubMed ID: 28791849
    [Abstract] [Full Text] [Related]

  • 11. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension.
    Robador PA, Moreno MU, Beloqui O, Varo N, Redón J, Fortuño A, Zalba G, Díez J.
    J Hypertens; 2010 Nov 11; 28(11):2219-26. PubMed ID: 20683337
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transforming growth factor beta in hypertensives with cardiorenal damage.
    Laviades C, Varo N, Díez J.
    Hypertension; 2000 Oct 11; 36(4):517-22. PubMed ID: 11040229
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension.
    Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H.
    Hypertension; 1996 Jul 11; 28(1):22-30. PubMed ID: 8675258
    [Abstract] [Full Text] [Related]

  • 18. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide.
    Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A.
    Circ J; 2007 May 11; 71(5):716-21. PubMed ID: 17456997
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.